Compass Therapeutics, Inc.
NASDAQ:CMPXBiotechnology
-$0.03 today
- Market cap
- $110.03M
- Beta
- 0.74
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.37
Volume 1.79M
Average 7.64M
CMPX Operating Cash Flow
Cash generated by the company's core business operations during the period.
Compass Therapeutics, Inc.NASDAQ: CMPX
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $17.27M (cash outflow) rose 30.7% year over year, ahead of the +20.4% change in trailing-twelve-month operating cash flow. Sequentially, it rose 30.3% from the prior quarter. Over 3 fiscal years it compounded at +12.9% a year.
Context
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +30.7% holds above the trailing-twelve-month pace of +20.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (49.14M) USD
- Year-over-year change
- -9.6%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (49.14M) | -9.6% |
| FY2024 | 2024-12-31 | (44.86M) | -10.4% |
| FY2023 | 2023-12-31 | (40.62M) | -19.0% |
| FY2022 | 2022-12-31 | (34.13M) | -73.5% |
| FY2021 | 2021-12-31 | (19.67M) | — |
Operating Cash Flow vs competitors
How CMPX compares with its peers on the latest reported figures
- CMPX's LTM Mar 2026 operating cash flow of $53.2M is the 7th largest of the 11 companies compared; the peer median is $61.48M.
- Its year-over-year change of +20.4% is the 3rd highest of 10, against a peer median of -15.5%.
- Over three fiscal years its annual growth of +12.9% compares with a peer median of +6.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $228.9M | +26.8% | +42.6% | 360.5% | |
| LTM Mar 2026 | $170.26M | -1969.0% | -2.9% | 306.6% | |
| LTM Mar 2026 | $129.45M | -15.5% | +8.0% | 146.7% | |
| LTM Mar 2026 | $94.76M | -33.7% | +10.3% | 957.8% | |
| LTM Mar 2026 | $63.56M | -913.9% | -14.8% | — | |
| LTM Mar 2026 | $59.4M | +16.7% | -1.8% | 1330.4% | |
| LTM Mar 2026 | $53.2M | +20.4% | +12.9% | — | |
| LTM Mar 2026 | $38.8M | -76.8% | -8.6% | 55.7% | |
| LTM Mar 2026 | $34.91M | +22.4% | +6.7% | — | |
| LTM Dec 2025 | $23.59M | — | — | 20.4% | |
| LTM Mar 2026 | $10.01M | -3.8% | +19.1% | — | |
| Peer median (excluding CMPX) | $61.48M | -15.5% | +6.7% | 306.6% | |
Competitors are the stored peer set for CMPX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (82.18M) | (39.23M) | (42.49M) | (49.38M) | (66.49M) |
| Depreciation & Amortization | 1.62M | 1.9M | 1.89M | 1.75M | (1.4M) |
| Deferred Income Tax | 50.58M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.03M | 5.33M | 6.12M | 8.56M | 8.37M |
| Change in Working Capital | 6.25M | (1.26M) | (2.91M) | (4.14M) | 9.18M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (194K) | 2.52M | 708K | (1.84M) | (664K) |
| Other Working Capital | 6.44M | (3.78M) | (3.62M) | (2.3M) | 9.84M |
| Other Non-Cash Items | 41K | (871K) | 5.97M | (1.65M) | 1.2M |
| Operating Cash Flow | (19.67M) | (34.13M) | (40.62M) | (44.86M) | (49.14M) |
| Capital Expenditures | (1.57M) | (212K) | (30K) | (44K) | (25K) |
| Acquisitions (Net) | 116K | 176K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (200.12M) | (155.42M) | (88.16M) | (194.56M) |
| Sales of Investments | 0 | 48.96M | 182.41M | 134.97M | 101.28M |
| Other Investing Activities | (318K) | (150.99K) | 27K | 0 | 0 |
| Investing Cash Flow | (1.77M) | (151.2M) | 26.97M | 46.77M | (93.31M) |
| Debt Repayment | — | — | — | 0 | 0 |
| Common Stock Issued | 128.27M | 76.24M | 3.09M | 18.11M | 130.64M |
| Common Stock Repurchased | 0 | 0 | (159) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (281K) | (480K) | (159K) | (775K) | (1.03M) |
| Financing Cash Flow | 118.61M | 75.76M | 2.94M | 17.34M | 129.61M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 97.18M | (109.57M) | (10.72M) | 19.26M | (12.84M) |
| Free Cash Flow | (21.23M) | (34.34M) | (40.65M) | (44.9M) | (49.17M) |
Compass Therapeutics, Inc.
NASDAQ:CMPX
Intrinsic Alpha fair value
Locked
Current Price
$0.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.